A C C E P T E D M A N U S C R I P T Introduction
Parkinson's disease (PD) is the second most frequent neurodegenerative disorder worldwide. The loss of dopamine through denervation in the striatum as a result of progressive neuronal degeneration in the substantia nigra pars compacta (SNpc), is the primary neurotransmitter marker of the disease (de Lau and Breteler, 2006) . Since dopamine does not cross the digestive mucosa or the blood brain barrier, its lipophilic precursor L-dopa has been employed and remains the pivotal oral medication (Chaudhuri and Schapira, 2009 ).
However, after persistent use over several years, many pharmacokinetic drawbacks contribute to the occurrence of motor fluctuations and dyskinesia (Fahn and Parkinson study group, 2005) . Indeed L-dopa has a short half-life, limited and variable reabsorption through the digestive and blood brain barriers and potentially harmful peripheral distribution. Moreover, L-dopa requires the aromatic L-amino acid decarboxylase for the synthesis of dopamine, which declines in the striatum with disease progression (Ciesielska et al., 2015) .
Under normal conditions, dopaminergic neurons of the SNpc generate a short phasic discharge firing pattern. The frequency and duration of this pattern embeds them in the tonic low-frequency background range and maintains the striatal dopamine concentration at a relatively constant level (Paladini and Roeper 2014) . However, in the dopamine-depleted state relevant to PD, intermittent oral doses of L-dopa can induce discontinuous stimulation of striatal dopamine receptors that in turn contribute to dysfunctional dopaminergic pathways.
Thus, continuous dopamine administration is considered more physiologically appropriate by preventing oscillations in neurotransmitter concentration (Olanow et al., 2006, Gershanik and Jenner, 2012) . De Yebenes et al. (1987) previously demonstrated that intracerebroventricular (i.c.v.) administered dopamine with an anti-oxidant adjuvant (sodium metabisulfite; SMBS) transiently improved motor handicap and increased dopamine in rat brains with unilateral neurotoxin 6-hydroxydopamine (6-OHDA)-induced damage as well as 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) intoxicated monkeys. The clinical feasibility of this administrative route has been supported by two PD patient case reports of dopamine infusion to the frontal ventricle, whereby a reduction in motor handicap was observed (Venna et al., 1984; Horne et al., 1989) . However, both preclinical and clinical reports also highlight two overriding problems that prevented further development; (i) occurrence of tachyphylaxia and
(ii) oxidation of dopamine causing enhanced dopamine metabolism and oxidative stress.
Dopamine oxidation can be limited by preparing, storing and administering dopamine in very low oxygen conditions. In addition, greater advances in programmable pumps now
minimize tachyphylaxia by allowing administration of a lower effective dopamine dose in accordance with the circadian cycle. The purpose of this study is to demonstrate that continuous circadian i.c.v. administration of dopamine close to the striatum is feasible, efficient and safe in mouse and rat models of PD, supporting clinical development of this strategy to be revisited in PD patients with L-dopa related complications with dyskinesia.
Material and methods

LUHMES cells
Lund human mesencephalic (LUHMES) cells (gift from Pr. Marcel Leist; CAAT, University of Konstanz, Germany) were grown for 2 days in differentiation medium (advanced DMEM/F12, 1 × N2 supplement, 2 mM l-glutamine, 1 mM cAMP, 1 μg/ml tetracycline and 2 ng/ml recombinant GDNF) before seeding in 6 or 24 well plates and grown for a further 3 days before treatment. See supplementary material for details.
After 5 days of differentiation, LUHMES cells were treated with 1-methyl-4-phenylpyridinium (MPP+; 5µM) for 24 hours (h) before exposure to dopamine or L-3,4-dihydroxyphenylalanine (L-dopa)(Sigma Aldrich, St Louis, MO, USA) for a further 24h.
Viability was measured on 10,000 cells by flow cytometry (CANTO II) using propidium iodide (0.5µM) and analysed with DIVA software (BD Biosciences, Le pont de Claix, France).
Rodent neurotoxic models
All experiments were carried out in accordance with the recommendations for the care and use of laboratory animals (FELASA) as well as European Directive 86/609-2010/63/UE guidelines for animal experimentation. Protocols were approved by an Ethical Committee (Nord-Pas-de-Calais;CEEA75) to induce MPTP neurotoxicity on 5 month old C57Bl/6J mice (Ethical permit number: CEEA102012) or 6-OHDA neurotoxicity in 5 month old Wistar rats (Ethical permit number: CEEA 262011 and CEEA2016020911207601). Animals were grouphoused (10 mice or 5 rats per cage) and a habituation period of 7 days after transportation was respected before any experimental manipulation was carried out. All surgery was performed under anesthesia and all efforts were made to minimize suffering.
Experimental procedures for obtaining the MPTP mice and 6-OHDA rat models have been previously described (Laloux et al., 2012) . Briefly, mice received four intraperitoneal 
Treatment parameters for rodent models
L-dopa methyl ester hydrochloride (Sigma Aldrich, St Louis, MO, USA) was extemporaneously prepared in saline with 12 mg/kg Benserazide, independent of L-dopa dose (Cenci and Lundblad, 2007) . During the treatment regime L-dopa was administered intraperitoneally (i.p.) twice a day at doses previously reported for mice and rats (Espadas et al., 2012; Fornai et al., 2000) . Anaerobia-dopamine (A-dopamine, Patent #WO2015173258 A1) was prepared by dissolving in saline (0.9% NaCl, pH 7.4) before the osmotic pump was filled and connected to a brain infusion cannula under an atmosphere that contained 5%
hydrogen, 5% carbon dioxide and 90% nitrogen (BACTRON anaerobic/environmental chamber). Before stereotaxic surgery, osmotic pumps were primed under anaerobia for over 4 hours at 37°C. The stability of the A-dopamine solution in osmotic pump at 37°C was checked for up to 30 days using an HPLC assay for dopamine (data not shown). Chronic dopamine treatments (30 days) on rats began 3 weeks after unilateral 6-OHDA or saline cerebral injection. Only 6-OHDA rats displaying more than 5 turns/min in the Apomorphine-induced rotation test were used in the study (75% of the rats). Rats were divided into 6 experimental groups; saline only, 6-OHDA only, 6-OHDA + A-dopamine (3 different doses) and 6-OHDA + L-dopa. After surgical cannula-pump (programmable IPRECIO® SMP200 pumps) implantation on the 6-OHDA lesion side (see supplemental material for details) A-dopamine was administered to the right lateral ventricle by i.c.v at a rate of 3µl/hr for 16h out of 24h (Zeitgeber time 13 to 5). Rats were housed in a 12hr
light/12hr dark cycle and the implanted pump was set to deliver dopamine over 16hrs,
predominantly during the active (dark) phase of the rat while it is awake. However this also included part of the resting (light) phase to allow behavioural assessments under treatment (see supplemental image 1 for the time delivery settings). L-dopa was administered by i.p.
twice a day over the same treatment period.
Behavioral assessment
Actimetry. Spontaneous motor activity in mice and rats was recorded by an actimeter (Panlab, Barcelona, Spain) over 10 minutes (Laloux et al., 2012) . This apparatus and the associated Actitrack software allowed distance travelled, speed and rearing behavior to be measured based on infrared beams obstructions.
Drug-induced rotation test.
To assess rotational asymmetry, contralateral rotations over 10 minutes were counted 30 minutes after rats were subcutaneously (s.c.) injected with apomorphine (APOKINON®; 0.5 mg/kg). Only nigro-striatal-lesioned animals performing >5
turns/min were included in the experimental cohorts as these have more than 80% depletion of striatal dopamine terminals (Francardo et al., 2011) .
Cylinder test. Rats performed the cylinder test (Schallert et al., 2000) to evaluate spontaneous forelimb lateralization. The number of vertical forepaw explorations on the cylinder wall using the right or left paw was assessed during 3 minutes.
Stepping test. The Stepping test (Olsson et al., 1995) is designed to monitor forelimb akinesia.
Rats were gently dragged by the hindquarters across a bench over a distance of 0.90 m in 5 sec. Supportive leg adjustments by the rat were counted over 3 consecutive trials.
Treatments-induced dyskinesia assessment. The principles and classifications of dyskinesia
have been standardized and well-described for the rat (Cenci and Lundblad, 2007) . Following the injection of L-dopa or during treatment, dyskinesia analysis consisted of scoring rat motor behavior for 1 min every 20 min over 3 h. Based on duration and persistence of the dyskinetic behaviour during the 1-min observation period, abnormal involuntary movements (AIM) were divided into locomotive, axial, forelimbs and orolingual subtypes. For each subtype, a score from 0 to 4 was given to culminate into an overall dyskinesia score for each rat.
Nigro-striatal tyrosine hydroxylase staining and analysis
After treatment and behavioural analysis, mice and rats were sacrificed and 4% paraformaldehyde perfused brains were microscopically sectioned by cryostat for tyrosine 
Striatum analysis by HPLC
Striatal samples were homogenized (0.1M perchloric acid, 2.6 mM sodium disulfite, 0.7 mM EDTA, 25 ng/ml 3,4-dihydroxybenzilamine) before supernatants were separated by HPLC using a Chromsystems column for Dopamine, DOPAC and 5-cysteinyl-dopamine or an
Uptisphere column for HVA. Glutathione status (i.e. GSSG/ GSH) was also determined chromatographically after derivatization with orthophthalaldehyde was accomplished using isocratic elution on a Symmetry Shield C18 column (Waters SAS, France) (See supplemental material for details).
Statistical analysis
All data were expressed as mean ± SEM, mostly as a percentage from the saline or vehicle control group. For all parameters, a one-way ANOVA was used to assess group effect, followed by LSD Fisher post hoc test. If data did not follow a Gaussian distribution, a
Kruskal-Wallis variance analysis was performed, followed by Mann-Whitney post hoc test.
The threshold for statistical significance was set to p<0.05. All statistical analyses were performed with IBM SPSS Statistics (Version 20).
Results
Dose-related effects of dopamine on dopaminergic neurons in vitro
In order to eliminate the possibility of dopamine being systematically deleterious, we demonstrated in vitro that low to moderate dopamine dose (≤3µM) prevented MPP+ induced neurotoxicity whereas L-dopa was substantially less efficient ( Figure 1 ). Conversely, high doses of either dopamine or L-dopa (10-to 100-fold higher) had moderate to no neuroprotective effect and a very high dose of dopamine (1000-fold higher) increased cell death. The optimal window of neuroprotection for both dopamine and L-dopa was determined to be 0.05 -0.2µM. In order to avoid the use of SMBS, due to its poor anti-oxidant properties with additional detrimental effects (Nair et al., 2003) , an A-dopamine preparation protocol was developed to maintain the neurotransmitter in an anaerobic environment throughout the filling and pump priming procedures. Similar to O-dopamine with SMBS, high A-dopamine dose (240 µg/day) without SMBS improved motor impairment but was still deleterious to SNpc TH-ir+ neurons ( Figure 2B ). However, A-dopamine at 120 µg/day without SMBS improved motor activity without neuropathology to the nigro-striatal pathways (Figure 2A ). Very low intensity in brown discoloration of the brain's ventricular walls was observed in some mice (~30%).
A C C E P T E D
Functional recovery induced by A-dopamine
The safety profile of A-dopamine was further studied in MPTP-treated mice using a broad dose range (40 -120 µg/day) and compared to O-dopamine (60 -120 µg/day) and i.p. induced by A-dopamine at 60 and 80 µg/day was determined to be optimal whereas 120µg/day also reversed TH-ir+ terminal loss in striatum. Conversely, neither O-dopamine nor L-dopa prevented reduced TH-ir counts after MPTP in the SNpc and striatum.
ACCEPTED MANUSCRIPT
A C C E P T E D M A N U S C R I P T Diffusion and metabolism of A-dopamine within the brain
Lateral ventricular administration of 80 and 120 µg/day A-dopamine demonstrated good diffusion into the ipsilateral striatum post MPTP intoxication. Similar results were observed upon peripheral L-dopa administered at 50 and 100 mg/day, with 120 µg/day Adopamine and 100 mg/day L-dopa having comparable maximal diffusion ( Figure 3A ).
The reduction in DOPAC and HVA metabolites caused by MPTP in the striatum (75% loss) was significantly restored by 60 to 120 µg/day of A-dopamine and in a dose-dependent manner with L-dopa ( Figure 3B-C) . Of note, A-dopamine preferentially increased HVA whereas L-dopa favored a DOPAC increase, potentially revealing alternate metabolism pathways.
As bilateral distribution from the lateral ventricle through the third ventricle to both striatum is not evident in mice, A-dopamine did not alter the contralateral striatal level of dopamine or metabolites (except for the highest dose which significantly increased HVA).
Changes to A-dopamine oxidative metabolism
The oxidative metabolism of dopamine was determined by 5-cysteinyl dopamine; a glutathione-dependent covalent modification of dopamine quinones derived from dopamine oxidization (Chen et al., 2008) . Levels were not modified with doses of A-dopamine below 120 µg/day (i.e. ≤ 0.3 nmol/mg) or with the peripheral L-dopa treatment (undetectable) (Suppl. Table 1 ). Glutathione was strongly oxidized by MPTP intoxication (as indicated by low GSH/GSSG ratio) but the GSH/GSSG ratio was significantly increased by both Adopamine and L-dopa treatments. This suggested that both were equally protective in regard to the redox state of dopaminergic neurons.
Lack of tachyphylaxia following chronic A-dopamine stimulation in 6-OHDA rats
In 6-OHDA treated rats, A-dopamine was chronically administered by i.c.v for 30 days (16h/day) at 3 doses (1, 2 and 3 mg/day). This regime was compared behaviorally to peripherally administered L-dopa (6 mg/kg twice daily) over the same time period. For Adopamine, 'stepping' and the 'cylinder' tests were consistent with actimetry analysis. At both 15 and 30 days post-neurotoxin injection, a dose response effect was observed for Adopamine, whereby 1mg/day was considered ineffective, 2mg/day restored the mean locomotive speed and distance of the rat and 3mg/day induced over-activity ( Figure 4A-D) .
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Observationally, it was noted that differences between 2 and 3 mg/day at 15 days were reduced after 30 days of treatment. As previously reported 6-OHDA rats responded well to Ldopa treatment in all three motor tests (Laloux et al., 2012) despite an over compensation after 30 days of treatment of the contralateral paw in the cylinder and stepping test ( Figure 4C & D).
Lack of dyskinesia and dopaminergic sensitization following A-dopamine stimulation
Chronic peripheral treatment with L-dopa (6 mg/kg twice daily for 30 days) induced a consistent and high dyskinesia score compared to sham or 6-OHDA-treated rats (Table 1) .
However throughout the treatment period, all doses of A-dopamine (1-3mg/day) produced minimal abnormal locomotive movements and dyskinesias was undetectable (Video 1).
Moreover, as previously reported (Bordet et al., 2000) , by the end of the 30 day treatment period behavioral dopaminergic sensitization associated with dyskinesia was evident in Ldopa treatment ( Figure 4E ). Conversely, a reduced number of apomorphine-induced rotations were observed with A-dopamine administration.
Good safety profile of A-dopamine
Neither L-dopa or A-dopamine had supplementary deleterious effects on the remaining 10% TH-ir+ neurons after ipsilateral 6-OHDA injection ( Figure 4G & H) . Highest doses of A-dopamine may even have had a positive impact ( Figure 4G ). A significant body weight gain was observed in higher doses of A-dopamine and may be attributed to dopamine effect on motivation to eat (via its action on mesolimbic system) or an orexigen effect (via the hypothalamic system). In L-dopa treated rats this gain was reduced after 30 days compared to shams ( Figure 4F ) and could be associated with higher daily energy expenditure as a result from the observed dyskinesias. No overall harmful effects could be attributed to body weight changes and no anatomopathological alteration of heart, liver, pancreas, spleen, kidney, spinal cord, eye, and brain were observed after 30 days of either treatment.
Discussion
Results obtained in these three different models of PD demonstrate a promising therapeutic regime for A-dopamine treatment. In vitro, a positive effect of dopamine was observed on LHUMES cell survival. In vivo, A-dopamine restored motor function and
induced a dose dependent increase of nigro-striatal tyrosine hydroxylase positive neuron survival in mice after 7 days of MPTP insult, suggesting a strong safety profile that was not evident with either O-dopamine or L-dopa. In a chronic rat model using 6-OHDA-lesioning, continuous circadian i.c.v injection of A-dopamine over 30 days also improved motor activity without occurrence of tachyphylaxia. Significantly, A-dopamine did not induced dyskinesia or behavioral sensitization as observed with peripheral L-dopa treatment.
Similar to L-dopa treatment in previous clinical and preclinical studies, inconsistencies are reported in the use of dopamine, whereby high doses are described as neurotoxic (Hastings et al., 1996) but sub-toxic concentrations have neuroprotective and neurotrophic effects (Jia et al., 2008) . We confirm that the positive impact of dopamine on TH-ir+ neurons of the nigro-striatal pathways was predominantly dependent on dose, but the oxidation state of dopamine is also paramount. As well as illustrating that O-dopamine was detrimental to neurons, higher A-dopamine concentrations in the presence of MPTP also induced significant neurotoxic 5-cysteinyl-DA production. However a low A-dopamine dose promoted TH-ir+ neuronal counts with no evidence of oxidized dopamine.
To our knowledge, this is the first to describe such a SNpc and striatal TH-ir+ neuronal plasticity with dopamine administration. We suggest that this could be explained by a culmination of events. Low A-dopamine dose prevented TH stained neuronal death caused by synaptic inactivity (Jeon et al., 1995) , restored dopaminergic cell markers required for maintained dopamine production (Datla et al., 2001) , scavenged rather than promoted ROS formation (Agil et al., 2006) and may have enabled a switch in striatal neurons from a serotonergic to dopaminergic phenotype (Carta et al, 2007) .
A viable optimal therapeutic regime would be to continuously compensate the deficit in dopamine that mediates neuronal communication within the SNpc. A continuous nonpulsatile i.c.v administration better mimics the physiological released of dopamine caused by the tonic background activity of SNpc neurons (Olanow et al., 2006) . In animal models of PD, several studies have proven the efficacy of continuous dopamine infusion. Hargraves and Freed (1987) showed that striatal injection of 12 or 120 µg/day dopamine with SMBS (during 13 days) reduced locomotive abnormalities, whereas others studies confirmed this result with alternative administration parameters (e.g. i.c.v injection, dose at 240 µg/day or time over 7 days) (De Yebenes et al., 1987; Kroin et al., 1991) . The first human case report (Venna et al., 1984) described a good tolerance to dopamine infusion over 1 year. A subsequent human case report (Horne et al., 1989) supports our current data by illustrating that long-term i.c.v.
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13 dopamine provides a smooth control of motor symptoms. However until now, concerns regarding dopamine oxidation and patient tachyphylaxia have restricted further development.
Of note, PD patients from previous studies received O-dopamine and at the same dose throughout a 24 hours cycle. Prior experience obtained from the use of an apomorphine pump and duodopa® has identified the need to differentiate between diurnal and nocturnal minimum efficient dose in order to avoid worsening motor fluctuations (Devos and French DUODOPA study group, 2009; Drapier et al., 2016) .
In summary, far from being deleterious, we observe that when dopamine levels and and right step adjustment in the stepping test (D) were evaluated. All data was compared to vehicle control set at 100% within the actimetry arena (A&B) or 50% representing equal
forelimb preference (C&D). For apomorphine induced rotation, measurements were taken immediately after 6-OHDA insult but before treatment (D0) as well as 30 days after treatment (D30) in the same treatment parameters (E). Rat body weight gain during the 30 days of treatment (F) as well as TH-ir+ optical density in dorsal striatum (ipsilateral and contralateral) (G) and TH-ir+ neuronal count in SNpc (H) were also evaluated. All data are expressed in percentage from Vehicle rats, means ± SEM (n=10/group). Significant differences * vs.
vehicle rats, # vs. untreated 6-OHDA rats, p<0.05 (one-way ANOVA and LSD Fisher posthoc tests or Mann-Whitney comparison test). Data are expressed in means ± SEM (n=10 animal per group). Significant differences * vs.
untreated 6-OHDA rats, # vs. L-dopa treated 6-OHDA rats, p<0.05 (non-parametric Kruskal- 
